NCT06029127Not yet recruiting
A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer
A Phase 2, Open-label, Randomized, Multi-arm Study of BGB-A445 in Combination With Investigational Agents in Non-Small Cell Lung Cancer Patients Previously Treated With Anti-PD-(L)1 Antibody
BeiGenePhase 2ClinicalTrials.govdrug
Study focus
- Disease/Condition
- Non-Small Cell Lung Cancer
- Drug/Device/Intervention
- BGB-A445
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- BeiGene
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Oct 01, 2023
- End date
- May 01, 2026
- Enrollment
- 100 participants
Primary outcome
Overall Response Rate
Summary
The main objective of this study is to evaluate the anti-tumor activity of BGB-A445 plus
 investigational agents in participants with non-small cell lung cancer (NSCLC)
ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06029127
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06029127 through Pure Global AI's free database. This Phase 2 trial is sponsored by BeiGene and is currently Not yet recruiting. The study focuses on Non-Small Cell Lung Cancer. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.